Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 269-273

  Song, Xueqin ^a,b,c   Fan, Xiaoduo ^c   Song, Xinwen ^b   Zhang, Jianjiang ^a   Zhang, Wei ^a   Li, Xue ^a   Gao, Jinsong ^a   Harrington, Amy ^c   Ziedonis, Douglas ^c   Lv, Luxian ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adiponectin; Inflammation; Interleukin 1 ; Interleukin 6; Schizophrenia; Tumor necrosis factor

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE OXIDASE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; SCHIZOPHRENIA; UPREGULATION;

ADIPONECTIN; INFLAMMATION; INTERLEUKIN-1Β; INTERLEUKIN-6; SCHIZOPHRENIA; TUMOR NECROSIS FACTOR-Α;

ADIPONECTIN; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84884157037     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.044     Document Type: Article

References (44)

1. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 2001, 62(Suppl. 7):22-31.
2. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65:1335-1342.
3. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999, 271:126-128.
4. Beumer W., Drexhage R.C., De Wit H., Versnel M.A., Drexhage H.A., Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012, 37:1901-1911.
5. Camandola S., Mattson M.P. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin. Ther. Targets 2007, 11:123-132.
6. Chen C., Lu F.C., Department of Disease Control Ministry of Health, P.R.C. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed. Environ. Sci. 2004, 17:1-36. (Suppl.).
7. Cheng X., Folco E.J., Shimizu K., Libby P. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J. Biol. Chem. 2012, 287:36896-36904.
8. Elmslie J.L., Porter R.J., Joyce P.R., Hunt P.J., Shand B.I., Scott R.S. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust. N. Z. J. Psychiatry 2009, 43:53-60.
9. Fan X., Goff D.C., Henderson D.C. Inflammation and schizophrenia. Expert. Rev. Neurother. 2007, 7:789-796.
10. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007, 149:267-271.
11. Fan X., Borba C.P., Copeland P., Hayden D., Freudenreich O., Goff D.C., Henderson D.C. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr. Scand. 2013, 127:217-226.
12. Hattori Y., Hattori S., Kasai K. Globular adiponectin activates nuclear factor-kappaB in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care 2006, 29:139-141.
13. Haugen F., Ranheim T., Harsem N.K., Lips E., Staff A.C., Drevon C.A. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E326-E333.
14. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
15. Kong A.P., Chan N.N., Chan J.C. The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr. Diabetes Rev. 2006, 2:397-407.
16. Lappas M., Permezel M., Rice G.E. Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology 2005, 146:3334-3342.
17. Li F.Y., Cheng K.K., Lam K.S., Vanhoutte P.M., Xu A. Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol. (Oxf.) 2011, 203:167-180.
18. Liao W., Yu C., Wen J., Jia W., Li G., Ke Y., Zhao S., Campell W. Adiponectin induces interleukin-6 production and activates STAT3 in adult mouse cardiac fibroblasts. Biol. Cell. 2009, 101:263-272.
19. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32:9-15.
20. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Altamura C.A. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002, 54:281-291.
21. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., Yao J., Peters J.L. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 1995, 152:1291-1297.
22. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia. An integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
23. Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpe S., Steinbusch H.W., Leonard B.E., Kim Y.K. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 2011, 25:1576-1581.
24. Naudin J., Capo C., Giusano B., Mege J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr. Res. 1997, 26:227-233.
25. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339:172-177.
26. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., Lee S.J., Lee C., Paik I.H. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int. Immunopharmacol. 2006, 6:666-671.
27. Plata-Salaman C., Turrin N. Cytokine interactions and cytokine balance in the brain: relevance to neurology and psychiatry. Mol. Psychiatry 1999, 4:302-306.
28. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59:137-150.
29. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 1994, 90:311-315.
30. Runeson B.S., Rich C.L. Diagnostic and statistical manual of mental disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann. Clin. Psychiatry 1994, 6:181-183.
31. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
32. Senolt L., Pavelka K., Housa D., Haluzik M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006, 35:247-252.
33. Shoji T., Shinohara K., Hatsuda S., Kimoto E., Fukumoto S., Emoto M., Tahara H., Koyama H., Ishimura E., Miki T., Tabata T., Nishizawa Y. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005, 54:330-334.
34. Sirota P., Meiman M., Herschko R., Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res. 2005, 134:151-159.
35. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol. Psychiatry 2009, 65:481-488.
36. Thundyil J., Pavlovski D., Sobey C.G., Arumugam T.V. Adiponectin receptor signalling in the brain. Br. J. Pharmacol. 2012, 165:313-327.
37. Tomizawa A., Hattori Y., Kasai K., Nakano Y. Adiponectin induces NF-kappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab. Vasc. Dis. Res. 2008, 5:123-127.
38. Turer A.T., Scherer P.E. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012, 55:2319-2326.
39. Une K., Takei Y.A., Tomita N., Asamura T., Ohrui T., Furukawa K., Arai H. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur. J. Neurol. 2011, 18:1006-1009.
40. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63:106-113.
41. Villarreal-Molina M.T., Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012, 94:2143-2149.
42. Yang L., Tao L.Y., Chen X.P. Roles of NF-kappaB in central nervous system damage and repair. Neurosci. Bull. 2007, 23:307-313.
43. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65:940-947.
44. Zhang Z.J., Yao Z.J., Liu W., Fang Q., Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br. J. Psychiatry 2004, 184:58-62.